Impact of Ravulizumab on Patient Outcomes and Quality of Life in Generalized Myasthenia Gravis

References

• Punga AR, Maddison P, Heckmann JM, Guptill JT, Evoli A. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular disorders. Lancet Neurol. 2022;21(2):176–188. doi:10.1016/S1474-4422(21)00297-0
   PubMed Web of Science ®Google Scholar
• Huijbers MG, Marx A, Plomp JJ, LePanse R, Phillips WD. Advances in understanding of disease mechanisms of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):163–175. doi:10.1016/S1474-4422(21)00357-4
   PubMed Web of Science ®Google Scholar
• Verschuuren JJGN, Palace J, Murai H, Tannemaat MR, Kaminski HJ, Bril V. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):189–202. doi:10.1016/S1474-4422(21)00463-4
   PubMed Web of Science ®Google Scholar
• Masi G, O’Connor K. Novel pathophysiological insights in autoimmune myasthenia gravis. Curr Opin Neurol. 2022;35(5):586–596. doi:10.1097/WCO.0000000000001088
   PubMed Web of Science ®Google Scholar
• Damato V, Spagni G, Monte G, et al. Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis. J Neurol Neurosurg Psychiatry. 2022;93(9):995–1000. doi:10.1136/jnnp-2022-329284
   PubMed Web of Science ®Google Scholar
• Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018;11:1756285617749134. doi:10.1177/1756285617749134
   Web of Science ®Google Scholar
• Bacci ED, Coyne KS, Poon JL, Harris L, Boscoe A. Understanding side effects of therapy for myasthenia gravis and their impact on daily life. BMC Neurol. 2019;19(1):335–347. doi:10.1186/s12883-019-1573-2
   PubMed Web of Science ®Google Scholar
• Guastafierro E, Tramacere I, Toppo C, et al. Employment in myasthenia gravis: a systematic literature review and meta-analysis. Neuroepidemiology. 2020;54(4):304–312. doi:10.1159/000506310
   PubMed Web of Science ®Google Scholar
• World Health Organization. How to use the ICF: a practical manual for using the International Classification of Functioning, Disability and Health (ICF). In: Exposure Draft for Comment. Geneva, Switzerland: World Health Organization; 2013.
   Google Scholar
• Burns TM. History of outcome measures for myasthenia gravis. Muscle Nerve. 2010;42(1):5–13. doi:10.1002/mus.21713
   PubMed Web of Science ®Google Scholar
• Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA. Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle Nerve. 2022;65(6):630–639. doi:10.1002/mus.27476
   PubMed Web of Science ®Google Scholar
• Burns TM, Conaway M, Sanders DB. The MG Composite. A valid and reliable measure for myasthenia gravis. Neurology. 2010;74(18):1434–1440. doi:10.1212/WNL.0b013e3181dc1b1e
   PubMed Web of Science ®Google Scholar
• Bedlack RS, Simel DL, Bosworth H, Samsa G, Tucker-Lipscomb B, Sanders DB. Quantitative myasthenia gravis: assessment of responsiveness and longitudinal validity. Neurology. 2005;64(11):196. doi:10.1212/01.WNL.0000163988.28892.79
   Web of Science ®Google Scholar
• Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487–1489. doi:10.1212/WNL.52.7.1487
   PubMed Web of Science ®Google Scholar
• Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score a. Ann N Y Acad Sci. 1998;841(1):769–772. doi:10.1111/j.1749-6632.1998.tb11015.x
   PubMedGoogle Scholar
• Raggi A, Leonardi M, Schiavolin S, et al. Validation of the MG-DIS: a disability assessment for myasthenia gravis. J Neurol. 2016;263(5):871–882. doi:10.1007/s00415-016-8072-9
   PubMed Web of Science ®Google Scholar
• Burns TM, Sadjadi R, Utsugisawa K, et al. International clinimetric evaluation of the MG-Qol15, resulting in slight revision and subsequent validation of the MG-Qol15r. Muscle Nerve. 2016;54(6):1015–1022. doi:10.1002/mus.25198
   PubMed Web of Science ®Google Scholar
• Regnault A, Morel T, de La Loge C, Mazerolle F, Kaminski HJ, Habib AA. Measuring overall severity of myasthenia gravis (MG): evidence for the added value of the MG symptoms PRO. Neurol Ther. 2023. doi:10.1007/s40120-023-00464-x
   Web of Science ®Google Scholar
• Lehnerer S, Jacobi J, Schilling R, et al. Burden of disease in myasthenia gravis: taking the patient’s perspective. J Neurol. 2022;269(6):3050–3063. doi:10.1007/s00415-021-10891-1
   PubMed Web of Science ®Google Scholar
• Garzon-Orjuela N, van der Werf L, Prieto-Pinto LC, Lasalvia P, Castaneda-Cardona C, Rosselli D. Quality of life in refractory generalized myasthenia gravis: a rapid review of the literature. Intractable Rare Dis Res. 2019;8(4):231–238. doi:10.5582/irdr.2019.01121
   PubMed Web of Science ®Google Scholar
• Gelinas D, Parvin-Nejad S, Phillips G, et al. The humanistic burden of myasthenia gravis: a systematic literature review. J Neurol Sci. 2022;437:120268. doi:10.1016/j.jns.2022.120268
   PubMed Web of Science ®Google Scholar
• Andersen JB, Owe JF, Engeland A, Gilhus NE. Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study. Eur J Neurol. 2014;21(7):948–955. doi:10.1111/ene.12439
   PubMed Web of Science ®Google Scholar
• Gilhus N, Nacu A, Andersen JB, Owe JF. Myasthenia gravis and the risk of comorbidity. Eur J Neurol. 2015;22(1):17–23. doi:10.1111/ene.12599
   PubMed Web of Science ®Google Scholar
• Kliemec-Moskal E, Quirke M, Leite MI. Comorbidities in older patients with myasthenia gravis - Comparison between early- and late-onset disease. Acta Neurol Scand. 2022;145(3):371–374. doi:10.1111/ane.13549
   PubMed Web of Science ®Google Scholar
• Berrih-Aknin S, Palace J, Meisel A, et al. Patient-reported impact of myasthenia gravis in the real world: findings from a digital observational survey-based study (MyRealWorld MG). BMJ Open. 2023;13(5):e068104. doi:10.1136/bmjopen-2022-068104
   PubMed Web of Science ®Google Scholar
• Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375(6):511–522. doi:10.1056/NEJMoa1602489
   PubMed Web of Science ®Google Scholar
• Wolfe GI, Kaminski HJ, Aban IB. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol. 2019;18(3):259–268. doi:10.1016/S1474-4422(18)30392-2
   PubMed Web of Science ®Google Scholar
• Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;19(3):114–122. doi:10.1212/WNL.0000000000011124
   Google Scholar
• Baggi F, Andreetta F, Maggi L, et al. Complete stable remission and autoantibody specificity in myasthenia gravis. Neurology. 2013;80(2):188–195. doi:10.1212/WNL.0b013e31827b907b
   PubMed Web of Science ®Google Scholar
• Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141–149. doi:10.1002/mus.20950
   PubMed Web of Science ®Google Scholar
• Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of myasthenia gravis. Ther Adv Neurol Disord. 2019;12:1–16. doi:10.1177/1756286419832242
   Web of Science ®Google Scholar
• Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. 2021;14(1):7–16. doi:10.25122/jml-2020-0145
   PubMedGoogle Scholar
• Dalakas MC. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert Rev Clin Immunol. 2022;18(7):691–701. doi:10.1080/1744666X.2022.2082946
   PubMed Web of Science ®Google Scholar
• Sanderson NSR. Complement and myasthenia gravis. Mol Immunol. 2022;151:11–18. doi:10.1016/j.molimm.2022.08.018
   PubMed Web of Science ®Google Scholar
• Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc. 1997;52:267–280.
   Google Scholar
• Morgan BP, Chamberlain-Banoub J, Neal JW, et al. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin Exp Immunol. 2006;146(1):146–302. doi:10.1111/j.1365-2249.2006.03181.x
   PubMedGoogle Scholar
• Howard JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976–998. doi:10.1016/S1474-4422(17)30369-1
   PubMed Web of Science ®Google Scholar
• Muppidi S, Utsugisawa K, Benatar M, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019;60(1):14–24. doi:10.1002/mus.26447
   PubMed Web of Science ®Google Scholar
• Mantegazza R, Wolfe GI, Muppidi S, et al. Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension. Neurology. 2021;96(4):e610–e618. doi:10.1212/WNL.0000000000011207
   PubMed Web of Science ®Google Scholar
• Vissing J, Jacob S, Fujita KP, et al. “Minimal symptom expression” in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol. 2020;267(7):1991–2001. doi:10.1007/s00415-020-09770-y
   PubMed Web of Science ®Google Scholar
• Siddiqi ZA, Nowak RJ, Mozaffar T, et al. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. Muscle Nerve. 2021;64(6):662–669. doi:10.1002/mus.27422
   PubMed Web of Science ®Google Scholar
• Andersen H, Mantegazza R, Wang JJ, et al. Eculizumab improves fatigue in refractory generalized myasthenia gravis. Qual Life Res. 2019;28(8):2247–2254. doi:10.1007/s11136-019-02148-2
   PubMed Web of Science ®Google Scholar
• Sheridan D, Z-X Y, Zhang Y, et al. Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action. PLoS One. 2018;13(4):e0195909. doi:10.1371/journal.pone.0195909
   PubMed Web of Science ®Google Scholar
• Vu T, Meisel A, Mantegazza R, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022;1(5):1–12. doi:10.1056/EVIDoa2100066
   Google Scholar
• Meisel A, Annane D, Vu T, et al. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open label extension. J Neurol. 2023;270(8):3862–3875. doi:10.1007/s00415-023-11699-x
   PubMed Web of Science ®Google Scholar